Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive crawled date : 2021 - 09 - 29 save search
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
Published: 2021-09-29 (Crawled : 21:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.02%
H: 0.2%
C: -0.31%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.17%
H: 0.96%
C: -0.42%
covid positive results casirivimab phase 3 trial trial results
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
Published: 2021-09-29 (Crawled : 13:15) - globenewswire.com
EDIT | News | $5.355 -1.92% -1.96% 1.6M
|
Health Technology
|
| O: -6.58%
H: 2.45%
C: -13.27%
ongoing phase 1 positive trial phase 2 phase 3
Flora Growth Corp. (NASDAQ: FLGC) Ideally Positioned as Colombia Makes Cannabis Progress
Published: 2021-09-29 (Crawled : 13:00) - globenewswire.com
FLGC 4 | $1.74 4.09% 190K
|
Manufacturing
|
| O: 0.32%
H: 2.26%
C: -5.81%
cannabis growth positive nasdaq
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
positive results vaccine phase 3 topline order
FirstService Residential Extends Market Leadership Position in Florida
Published: 2021-09-29 (Crawled : 12:00) - globenewswire.com
FSV | $154.91 1.07% 1.06% 150K
|
Finance
|
| O: 0.16%
H: 1.24%
C: -1.45%
positive
Fortuna announces positive construction decision for its Séguéla gold Project in Côte d’Ivoire
Published: 2021-09-29 (Crawled : 10:00) - globenewswire.com
FSM | News | $4.64 -0.43% -1.49% 3.7M
|
Non-Energy Minerals
|
| O: -0.49%
H: 0.0%
C: -5.19%
positive
Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021
Published: 2021-09-29 (Crawled : 05:00) - globenewswire.com
CLDX | $36.975 -2.11% -2.15% 390K
|
Health Technology
|
| O: 0.0%
H: 1.03%
C: -2.59%
phase 1 positive phase 1b urticaria phase 2b
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.